Edwards Lifesciences Corp (EW, Financial) recently experienced a daily loss of 2.33%, contributing to a three-month decline of 1.78%. With an Earnings Per Share (EPS) of 2.32, investors might wonder if the stock is currently undervalued. This analysis delves into Edwards Lifesciences' valuation, providing insights into whether the current market price reflects the company's intrinsic value.
Company Overview
Founded in 2000 after spinning off from Baxter International, Edwards Lifesciences has become a frontrunner in the medical devices sector, specializing in products for structural heart disease. The company's portfolio includes surgical tissue heart valves, transcatheter valve technologies, and more. Notably, about 55% of its $6.10 billion in sales come from international markets. Currently, with a market cap of $51 billion and a stock price of $84.7, Edwards Lifesciences appears modestly undervalued when compared to the GF Value of $104.04.
Understanding GF Value
The GF Value is a proprietary measure calculated by GuruFocus to estimate the true value of a stock. It incorporates historical trading multiples, a GuruFocus adjustment factor based on past performance and growth, and projections of future business performance. For Edwards Lifesciences, the GF Value suggests that the stock is currently trading below its fair value, indicating potential for future gains.
Financial Strength and Stability
Investing in a company with solid financial health reduces risks of loss. Edwards Lifesciences boasts a cash-to-debt ratio of 2.43, outperforming 53.19% of its peers in the industry. This financial strength, rated 8 out of 10 by GuruFocus, indicates robustness in its financial structure.
Profitability and Growth Prospects
Edwards Lifesciences has maintained strong profitability, with an operating margin of 28.24%, ranking it higher than 94.33% of its industry counterparts. The company's consistent profitability over the past decade and its superior growth metrics, including a 3-year average annual revenue growth of 12.4%, underscore its potential for sustained performance.
Value Creation Metrics
An effective way to gauge a company's efficiency in value creation is comparing its Return on Invested Capital (ROIC) to its Weighted Average Cost of Capital (WACC). Edwards Lifesciences' ROIC of 22.28 significantly surpasses its WACC of 10.6, indicating effective management and promising shareholder returns.
Conclusion
In conclusion, Edwards Lifesciences (EW, Financial) presents a compelling case for investors seeking value. The stock's current market position, combined with strong financial health, profitability, and effective capital management, suggests it is undervalued. For those interested in deeper financial insights, Edwards Lifesciences' 30-Year Financials provide a detailed overview.
To explore other high-quality investment opportunities, consider using the GuruFocus High Quality Low Capex Screener.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
